Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

NCT00853827 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease (CAD)
Coronary Atherosclerosis

Interventions

DRUG: Placebo
DRUG: Aliskiren

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]